A detailed history of Exodus Point Capital Management, LP transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Exodus Point Capital Management, LP holds 441,584 shares of RVNC stock, worth $1.13 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
441,584
Holding current value
$1.13 Million
% of portfolio
0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$2.34 - $4.73 $1.03 Million - $2.09 Million
441,584 New
441,584 $1.14 Million
Q2 2023

Aug 10, 2023

BUY
$24.7 - $37.61 $675,421 - $1.03 Million
27,345 New
27,345 $692,000
Q3 2022

Nov 10, 2022

SELL
$14.33 - $28.47 $1.03 Million - $2.05 Million
-71,966 Closed
0 $0
Q2 2022

Aug 19, 2022

BUY
$11.52 - $20.4 $829,048 - $1.47 Million
71,966 New
71,966 $995,000
Q1 2022

May 13, 2022

SELL
$12.36 - $20.31 $544,297 - $894,391
-44,037 Closed
0 $0
Q4 2021

Feb 11, 2022

BUY
$12.46 - $27.87 $156,559 - $350,186
12,565 Added 39.92%
44,037 $719,000
Q3 2021

Nov 15, 2021

SELL
$25.78 - $33.21 $20,056 - $25,837
-778 Reduced 2.41%
31,472 $877,000
Q2 2021

Aug 16, 2021

SELL
$26.8 - $31.84 $1,849 - $2,196
-69 Reduced 0.21%
32,250 $956,000
Q1 2021

May 17, 2021

BUY
$24.03 - $29.97 $379,962 - $473,885
15,812 Added 95.79%
32,319 $903,000
Q4 2020

Feb 16, 2021

SELL
$23.41 - $28.34 $1.62 Million - $1.96 Million
-69,152 Reduced 80.73%
16,507 $468,000
Q3 2020

Nov 16, 2020

BUY
$23.23 - $34.3 $842,389 - $1.24 Million
36,263 Added 73.41%
85,659 $2.15 Million
Q2 2020

Aug 14, 2020

BUY
$12.6 - $26.55 $622,389 - $1.31 Million
49,396 New
49,396 $1.21 Million
Q1 2020

May 15, 2020

SELL
$12.46 - $27.81 $146,591 - $327,184
-11,765 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$11.66 - $20.15 $137,179 - $237,064
11,765 New
11,765 $191,000

Others Institutions Holding RVNC

About Revance Therapeutics, Inc.


  • Ticker RVNC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,305,696
  • Market Cap $212M
  • Description
  • Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...
More about RVNC
Track This Portfolio

Track Exodus Point Capital Management, LP Portfolio

Follow Exodus Point Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Exodus Point Capital Management, LP with notifications on news.